Boden William E, Cherr Gregory S, Eagle Kim A, Cannon Christopher P, Califf Robert M, Hirsch Alan T, Alberts Mark J, Criqui Michael, Creager Mark A, Massaro Joseph M, D'Agostino Ralph B, Steg P Gabriel, Bhatt Deepak L
Department of Cardiology, Buffalo General and Millard Fillmore Hospitals and Division of Cardiovascular Medicine, Schools of Medicine & Public Health, State University of New York at Buffalo, NY, USA.
Crit Pathw Cardiol. 2010 Sep;9(3):116-25. doi: 10.1097/HPC.0b013e3181e7f93e.
To assess the effect of prior cardiovascular interventions on long-term clinical outcomes in patients with symptomatic atherothrombosis, the risk factor profiles, treatment patterns, and 24-month outcomes of patients in the United States with and without prior cardiovascular intervention (catheter-based, surgical, or lower-limb amputation) enrolled in the global REACH (REduction of Atherothrombosis for Continued Health) Registry were compared. Of the 17,521 US outpatients aged > or =45 years with established coronary artery disease, cerebrovascular disease, or peripheral artery disease enrolled in the REACH Registry between December 1, 2003 and June 1, 2004 who had > or =1 follow-up visit, 11,925 (68.1%) had a previous cardiovascular intervention. Prior intervention was most common in patients with coronary artery disease (76.7%) and least common in patients with cerebrovascular disease (14.6%) at baseline. Patients with prior cardiovascular intervention were significantly more likely to be taking antihypertensive, antithrombotic, or lipid-lowering therapies than those without prior intervention (P < 0.0001 for each therapy). However, 24-month Kaplan-Meier event rates for the composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke were similar between patients with and without prior intervention (9.10% vs. 9.00%; P = 0.49). Thus, in the US REACH Registry, prior cardiovascular intervention was not associated with an increased risk of subsequent cardiovascular ischemic events during follow-up. Patients without prior cardiovascular intervention had a lower intensity of risk factor modification at baseline and appear to represent an at-risk, undertreated population.
为评估既往心血管干预措施对有症状动脉粥样硬化血栓形成患者长期临床结局的影响,对美国全球REACH(REduction of Atherothrombosis for Continued Health,持续健康动脉粥样硬化血栓形成减少)注册研究中登记的有或无既往心血管干预(基于导管的、外科手术的或下肢截肢)的患者的危险因素概况、治疗模式及24个月结局进行了比较。在2003年12月1日至2004年6月1日期间登记入REACH注册研究且进行了≥1次随访的17521名年龄≥45岁且患有确诊冠状动脉疾病、脑血管疾病或外周动脉疾病的美国门诊患者中,11925名(68.1%)曾有过心血管干预。基线时,既往干预在冠状动脉疾病患者中最为常见(76.7%),在脑血管疾病患者中最不常见(14.6%)。与无既往干预的患者相比,有既往心血管干预的患者更有可能接受抗高血压、抗血栓或降脂治疗(每种治疗P<0.0001)。然而,有或无既往干预的患者在心血管死亡、非致死性心肌梗死或非致死性卒中复合结局的24个月Kaplan-Meier事件发生率相似(9.10%对9.00%;P=0.49)。因此,在美国REACH注册研究中,既往心血管干预与随访期间随后心血管缺血事件风险增加无关。无既往心血管干预的患者在基线时危险因素修正强度较低,似乎代表了一个高危、治疗不足的人群。